Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Scinai Immunotherapeutics Ltd. - American Depositary Shares (NQ: SCNI )

3.345 +0.015 (+0.45%)
Streaming Delayed Price Updated: 11:23 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scinai Immunotherapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement
Via Investor Brand Network
Layoffs, Upheaval at CDC Trigger Fears on Handling Disease Outbreaks
Via Investor Brand Network
Topics Government Workforce
Exposures Layoff Political
Biomaterial Modification Could Yield Better Cancer Therapies, Study Finds
Via Investor Brand Network
New Trump Admin Could Drastically Change Research on Infectious Diseases
Via Investor Brand Network
Topics Government
Exposures Political
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences
Via Investor Brand Network
Cases of Parvovirus B19 Spike in the US
Via Investor Brand Network
New Drug Approach Could Roll Back Pancreatic Cancer Immunotherapy Resistance
Via Investor Brand Network
Researchers Identify Protein That Makes Cancer Evade Cell Therapy
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Nine-Month Financial Results and Business Update
Via Investor Brand Network
New Toolkit Launched to Boost Marburg Screening Readiness in the US
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Spotlight Innovative I&I Pipeline and CDMO Services at BIO-Europe 2024
Via Investor Brand Network
Researchers Shine Spotlight on New Barriers to Vaccination
Via Investor Brand Network
Exposures COVID-19
Whooping Cough Prevalence Rises in US as Missed Shots During Pandemic Come Home to Roost
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
Via Investor Brand Network
New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
Via Investor Brand Network
Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies
Via Investor Brand Network
Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
Via Investor Brand Network
Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.